2010 pharmacor news
August 31, 2010
An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market
August 25, 2010
Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 billion Decline in the Bipolar Disorder Drug Market
August 11, 2010
Owing to Generic Erosion of Key Agents Such As Effexor XR, Cymbalta/Xeristar, Cipralex/Seroplex and Lexapro, the Unipolar Depression Drug Market Will Decrease by Nearly 10 Percent in 2019
August 9, 2010
Driven Primarily by the Uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the Systemic Lupus Erythematosus Drug Market Will Quadruple to More Than $1.6 Billion in 2019
August 9, 2010
The Continued Uptake of Interleukin Inhibitors and TNF-Alpha Inhibitors and Increasing Penetration of Biologics Will Drive the Psoriasis Drug Market to Double to $6.8 Billion in 2019
August 5, 2010
After Peaking at $6.3 Billion in 2011, Generic Erosion of Atypical Antipsychotics Will Cause the Schizophrenia Drug Market to Decline to $5.2 Billion in 2019
July 28, 2010
In the Rheumatoid Arthritis Drug Market, the Uptake of Alternative Biologics Such as Roche/Chugai’s Actemra/RoActemra Will Erode the Market Share of TNF-Alpha Inhibitors Through 2019
July 21, 2010
Multiple Factors, Primarily Generic Erosion, Will Cause the Asthma Drug Market to Decline From $13.4 Billion in 2009 to Less Than $12.9 Billion in 2019
July 20, 2010
The Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019
July 12, 2010
The Launch of Eight Novel Disease-Modifying Therapies, Including the First Oral Agents Approved for the Indication, Will Drive Modest Growth in the Multiple Sclerosis Drug Market Through 2019
July 7, 2010
Drugs from Boehringer Ingelheim, Bayer/Johnson & Johnson, Bristol-Myers Squibb/Pfizer and Sanofi-Aventis Will Drive the Atrial Fibrillation Drug Market to Increase More Than Eight-Fold
July 6, 2010
Following Its Recent Approval in the United States and Europe for Osteoporosis, Prolia Will Garner Sales of More than $500 Million in 2019
June 29, 2010
Robust Annual Growth in the Renal Cell Carcinoma Drug Market Will be Driven by the Uptake of Glaxosmithkline's Votrient/Patorma and the Launches of Premium-Priced Emerging Therapies
June 28, 2010
The Uptake of Two Emerging Agents from Forest/Astrazeneca/Takeda and Trius Will Drive the MRSA Drug Market to Increase from $631 Million in 2009 to $752 Million in 2019
June 21, 2010
Rapid Uptake of Targeted Agents Will Drive the Gastric Cancer Drug Market to More Than Double to $1.5 Billion by 2019
June 15, 2010
Novartis/Mitsubishi Tanabe Pharma’s Gilenia Remains on Track to Achieve Blockbuster Sales in the Multiple Sclerosis Drug Market
June 2, 2010
For the Treatment of HIV, Three Novel Products From Gilead and Tibotec Will Earn Combined Peak Year Sales in Excess of $5 Billion
April 6, 2010
Driven by the Approval and Rapid Uptake of Avastin, the Ovarian Cancer Drug Market Will More Than Triple to Nearly $1.5 Billion in 2018
April 5, 2010
The Hospital-Acquired Infections Drug Market Will Decrease Modestly by 2018, Despite Generic Erosion of Key Brands, Intense Competition and Stringent Regulatory and Reimbursement Environments
March 31, 2010
Uptake of Reformulations of Conventional Analgesics Will Drive Annual Three Percent Growth in the Acute Pain Drug Market Through 2018
March 30, 2010
The Launches and Uptake of Novel Oral Anticoagulants Will Drive the Venous Thromboembolism Drug Market to Nearly Double by 2018
March 15, 2010
The Irritable Bowel Syndrome Drug Market Will More Than Triple From $459 Million in 2008 to $1.52 Billion in 2018
March 2, 2010
Ceftaroline Will Earn Peak Year Sales of Up to $200 Million in the Community-Acquired Pneumonia Drug Market
March 1, 2010
Boehringer Ingelheim’s Pradaxa Will Garner Blockbuster Sales of $1.3 Billion by 2018 in the Atrial Fibrillation Drug Market
FEBRUARY 25, 2010
In the Acute Coronary Syndrome Drug Market, the Uptake of Eli Lilly/Daiichi Sankyo’s Effient Will be Constrained by the Widespread Use of AstraZeneca’s Brilinta
FEBRUARY 24, 2010
In 2018, Sanofi-Aventis’s BSI-201 Will Garner Sales of $1.7 Billion in the Triple Negative Breast Cancer Drug Market
FEBRUARY 23, 2010
Emerging Oral Atypical Antipsychotics Will Garner Only Limited Uptake in the Schizophrenia Drug Market
FEBRUARY 22, 2010
Despite Minimal Uptake in the Crohn’s Disease Drug Market, Stelara’s Premium Price Will Result in Sales of Nearly $337 Million in 2018
FEBRUARY 18, 2010
Approval in Japan of New Formulation of Mitsubishi Tanabe Pharma’s Edaravone Will Further Bolster Its Position as the Top-Selling Therapy for Acute Ischemic Stroke
FEBRUARY 18, 2010
Vibativ’s Delayed Approval for Nosocomial Pneumonia Will Significantly Reduce Its Commercial Impact in the Methicillin-Resistant Staphylococcus Aureus Drug Market
FEBRUARY 16, 2010
For the Treatment of Benign Prostatic Hyperplasia, Competition From Emerging Novel Injectable Agents Will Reduce Botox’s Market Share
FEBRUARY 11, 2010
The Ulcerative Colitis Drug Market Will Nearly Double from $1.2 billion in 2008 to $2.1 Billion in 2018
FEBRUARY 10, 2010
Increasing Competition from Other Biologic Agents Will Continue to Erode Enbrel’s Dominance in the Psoriasis Drug Market
FEBRUARY 8, 2010
Emerging Combination Agent from Merck Will Garner Peak Year Sales of More Than $250 Million for the Treatment of Asthma
FEBRUARY 4, 2010
By 2018, AVEO Pharmaceuticals’ Tivozanib Will Garner Sales of up to $100 Million in the Renal Cell Carcinoma Drug Market
FEBRUARY 2, 2010
Hypertension Drug Market Will Be Constrained Through 2018 by a Pipeline Containing Very Few Novel Emerging Therapies
FEBRUARY 1, 2010
Benlysta Will Garner Sales of More Than $500 Million in 2018 in the Systemic Lupus Erythematosus Drug Market
JANUARY 27, 2010
Seroquel and Seroquel XR Will Garner Nearly One Quarter of Antipsychotics Sales for Major Depressive Disorder By 2013, Following Seroquel XR’s Approval as an Adjunctive Therapy for the Indication
JANUARY 26, 2010
Sumavel DosePro and Levadex are Forecasted to Earn Approximately $400 Million in Combined Sales by 2018 in the Migraine Drug Market
JANUARY 25, 2010
For Dyslipidemia Treatment, the Rapid Uptake of Dalcetrapib and Anacetrapib Will Drive $3.2 Billion in Sales of CETP Inhibitors in 2018
JANUARY 19, 2010
Telaprevir May be Viewed More Positively by Clinicians than Boceprevir For Hepatitis C Virus Treatment following their launches in 2011
JANUARY 18, 2010
Jazz PharmaceuticalS/UCB’s Sodium Oxybate Will Account for More
Than 15 Percent of the Fibromyalgia Drug Market in 2018
JANUARY 12, 2010
Boehringer Ingelheim’s Pramipexole ER Will Garner Peak Year Sales of $250 to $500 Million For the Treatment of Parkinson’s Disease
JANUARY 11, 2010
For the Treatment of Alzheimer’s Disease, Pfizer/Medivation’s Dimebon Will Garner Peak Year Sales of $1.5 Billion
JANUARY 7, 2010
Despite FDA Recommendation for Postmarketing Surveillance, Amgen’s Prolia Will Achieve Blockbuster Sales for Treatment of Osteoporosis
JANUARY 5, 2010
Despite FDA’s Letter to Merck Serono, Oral Cladribine is Still Expected to Be the First Oral Disease-Modifying Therapy to Launch for Multiple Sclerosis in the United States
JANUARY 6, 2010
Bristol-Myers Squibb/AstraZeneca’s Onglyza Will Garner Peak Year Sales of More Than $1 Billion in the Type 2 Diabetes Drug Market
JANUARY 4, 2010
In 2018, Coformulation of Rilpivirine and Truvada Will Achieve Blockbuster Sales of More Than $2 Billion in the HIV Drug Market
Analyzing and Forecasting the Commercial
Outlook for Drugs on the Market and in Research
and Development
What if your market research could update itself? What if you didn’t have to
make your own assumptions based on a nine-month old forecast? What if
when an event has a major impact on a drug market, your data and analysis
were updated with fresh scrutiny and new forecasts? Dynamic market
research will change the way you do your job…and it’s here ...
Decision Resources introduces a revolutionary new way to view your market
research with its newly re-designed Pharmacor. Below are important changes
to the Pharmacor brand that translate to a product that is of even higher value
to you.
- Pharmacor is no longer a series of static reports, but is now a
sophisticated, continually-evolving advisory service powered by a team
of analysts who monitor the world’s most commercially viable drug
markets on a daily basis throughout the year.
- Pharmacor’s expert analysts look for outcomes from conferences and
clinical trials as well as pricing and reimbursement changes, newly
announced regulatory and safety data and any other breaking news that
occurs in the world’s major pharmaceutical markets. The team then
analyzes the event, assesses its impact to the market and updates the
Pharmacor topic that is housed on Decision Resources’ product delivery
system, The Gateway.
- When significant events occur, our analysts may survey physicians and/or payers to evaluate their responses to major marketplace changes. This information is incorporated into the analysis and a review of the update is made available through quick response analyst call presentations providing immediate access to our decision support teams.
- Pharmacor also now includes an annualized 10-year forecast. By breaking out
our forecasts year by year, Pharmacor provides a more cohesive understanding
of events that impact the forecast in the years ahead. The precision that
accompanies our annualized forecasts produces the most comprehensive and
transparent market forecasts available anywhere.
Pharmacor's value proposition remains the same: to provide
concise analysis of the current and future earnings potential of
drugs on the market and in research and development in order
to enable users to make accurate investment decisions and
to correctly assess their competition. Pharmacor remains the
PREMIER source for:
- Assessing market size for different patient segments
- Evaluating future market size in terms of dollars
- Identifying target patients and key patient segments
- Reporting thought leader qualitative perceptions of
emerging therapies
- Identifying key shifts in medical practice and what is
driving them
- Analyzing how changes in medical practice will impact
treatment use
- Revealing how thought leaders expect emerging therapies
to be used
In Light of Safety Concerns, Abbott’s Briakinumab Faces a Rough Road Ahead in the Psoriasis Drug Market
Iva Holder, Ph.D.
September 7, 2010
10 a.m. ET, 4 p.m. CET
In this presentation, Dr. Holder will discuss Decision Resources’ revised forecast for Abbott’s briakinumab in the Psoriasis drug market ...
Learn more
AUGUST 4, 2010
The New HIV Pipeline: Where Have All the Drugs Gone and Has Virological Failure Doomed Rilpivirine’s Status as a Rising Star?
AUGUST 3, 2010
Who Will Be the Winners and Losers in the Obesity Wars? Fallout from the FDA Advisory Committee’s Vote on Qnexa
JULY 29, 2010
A Crushing Blow for Avastin? Assessing the Impact of an FDA Panel’s 12 to 1 Vote to Withdraw Avastin’s Marketing Approval for Breast Cancer
JULY 26, 2010
Venous Thromboembolism: How Will Sanofi-Aventis’s Semuloparin (AVE-5026) Compete in a Market That Will Soon Feature a Range of Oral Anticoagulants?
JULY 15, 2010
How Will Key Agents in Development Impact the Type 2 Diabetes Market? News from the ADA’s 70th Annual Scientific Sessions
JULY 13, 2010
Renal Cell Carcinoma: Will the Current Market Leader, Pfizer’s Sutent, be Challenged by the Changing Dynamics in this Crowded Market?
JULY 8, 2010
Rising Out of the Crowded Prostate Cancer Pipeline: Which New and Emerging Agents Will Become Market Leaders in 2019?
JUNE 28, 2010
What Impact Will the Emergence of Herceptin and Other Targeted Therapies Have on the Gastric Cancer Drug Market? News from ASCO
JUNE 25, 2010
Revlimid Continues to Show Promise as a Maintenance Treatment in Multiple Myeloma – News from ASCO
JUNE 24, 2010
Avastin and Other Key Emerging Agents Are Poised to Change the Landscape of Ovarian Cancer Treatment
JUNE 17, 2010
Prolia is Approved for the Treatment of Postmenopausal Osteoporosis: How Will It Compete in This Mature, Crowded Market?
JUNE 15, 2010
Psoriasis: The Uptake of Stelara in the United States: How are Physicians Integrating this IL-12/23 Inhibitor into a Market Dominated by TNF-alpha Inhibitors?
JUNE 11, 2010
Hepatitis C Virus: ADVANCE Clinical Trial Data Provides New Details Regarding Telaprevir’s Clinical Profile
JUNE 10, 2010
Hypertension: Does Novartis’s Tekturna Still Have What it Takes to Meet Expectations?
JUNE 2, 2010
Crohn’s Disease and Ulcerative Colitis: Surveyed Gastroenterologists React to Key Findings From the 2010 DDW Conference Regarding Humira, Cimzia and a Novel Botanical Product for IBD
MAY 27, 2010
Novel Antiarrhythmic Drugs for Atrial Fibrillation: Assessing the Challenges and Opportunities for Multaq, Brinavess/Kynapid and a New Prospective Contender – Ranexa
MAY 25, 2010
The Antibacterial Pipeline: Do Any Remaining Late-Stage Antibiotics Hold Promise?
MAY 18, 2010
COPD: How Will the Pending European Approval of Daxas and Its Expected Rejection in the U.S. Impact the Market?
MAY 14, 2010
Major Depressive Disorder: If Approved, Will TC-5214 Significantly Alter Physician Prescribing Habits in This Mature Market?
MAY 7, 2010
Hepatitis C Virus: The Withdrawal of Joulferon’s Marketing Authorization Application in Europe and Key Findings from the 2010 EASL Annual Meeting
MAY 6, 2010
TOLD YOU SO! Almost a Decade after Decision Resources First Forecasted Its Launch, Provenge is Approved for Prostate Cancer: Will It Become a Blockbuster and Pave the Way for Other Cancer Vaccines?
MAY 4, 2010
Motor Response Complications in Parkinson’s Disease: Neurologists’ Perceptions of Current Treatment and the Outlook for Emerging Therapies
APRIL 29, 2010
Multiple Sclerosis: Evaluating Neurologists’ Perceptions of the Risk of PML Associated With Tysabri and the Potential of a New Predictive Assay
APRIL 8, 2010
How Will Spiriva’s Expanded Labeling for Reducing COPD Exacerbations Affect its Uptake in the Market?
APRIL 7, 2010
How Will Ocrelizumab’s Suspension Impact the Rheumatoid Arthritis and Systemic Lupus Erythematosus Drug Markets?
APRIL 6, 2010
Stroke Prevention in Atrial Fibrillation - Will Betrixaban’s Clinical Profile Ensure Its Success?
APRIL 1, 2010
ACCORD Clinical Trial Fails to Show Benefit of Fibrates in Patients with Type 2 Diabetes – How Will This Impact the Dyslipidemia Market?
MARCH 25, 2010
Avastin Fails to Significantly Improve Overall Survival in a Phase III Trial in Prostate Cancer: What are the Market Implications?
MARCH 24, 2010
What Are the Most Compelling Drug Development Opportunities for the Treatment of Uncontrolled Asthma?
MARCH 18, 2010
Assessing the Impact of Dimebon’s Clinical Trial Failure on the Alzheimer’s Disease Drug Market
MARCH 16, 2010
The Increasing Challenges of the Maturing HIV Drug Market: Will Gilead’s Quad or Merck’s Vicriviroc Be Able to Compete?
MARCH 5, 2010
Avandia Makes Headlines Again: How Will the Renewed Controversy Impact the Type 2 Diabetes Drug Market?
FEBRUARY 25, 2010
Despite Safety Concerns, Sodium Oxybate is Poised for Approval in the U.S. for Fibromyalgia: Will It See Any Uptake in Primary Care?
FEBRUARY 12, 2010
Herceptin is Poised to Launch in Europe for Gastric Cancer: Will It Blaze the Trail for Other Targeted Agents in This Indication?
FEBRUARY 11, 2010
How Will Sibutramine’s Suspension in Europe Affect its Future in the United States and What Now Lies Ahead for the Obesity Drug Market?
FEBRUARY 10, 2010
Rheumatoid Arthritis: Will Actemra Ultimately Steal Market Share from the TNF-Alpha Inhibitors?
FEBRUARY 4, 2010
Benign Prostatic Hyperplasia: How Will the Discontinuation of Ozarelix and Launches of PRX-302 and NX-1207 Impact the Novel Injectables Landscape for BPH?
JANUARY 15, 2010
Sanofi-Aventis’s Novel Agent Emerges as an Effective Treatment for Prostate Cancer: Which Current Drugs Will Lose Market Share to Cabazitaxel?
JANUARY 14, 2010
Ceftobiprole’s Non-Approval in the U.S. Changes the Forecast for MRSA and Community-Acquired Pneumonia – Who Will Get the Projected $150 Million?
DECEMBER 9, 2009
Vying for Market Share in Triple Negative Breast Cancer - Will BSI-201 be a Worthy Competitor to Avastin?
NOVEMBER 20, 2009
After 50 Years, a New Lupus Drug Finally Emerges – If Approved, How Will Benlysta Impact the Market?
NOVEMBER 19, 2009
The Battle for Market Supremacy in Hepatitis C Virus: Which Drug Will Emerge on Top – Telaprevir or Boceprevir?
NOVEMBER 17, 2009
Three Late-Stage Obesity Therapies Close in on the Finish Line – Which Agents Will Have the Greatest Impact on the Market?
NOVEMBER 10, 2009
Do Newcomers Cimzia and Simponi Pose a Threat to Established TNF-alpha Inhibitors in the Rheumatoid Arthritis Market?
OCTOBER 21, 2009
Will Medivation’s MDV-3100 Steal Market Share from AstraZeneca’s Casodex in the Prostate Cancer Drug Market?
OCTOBER 15, 2009
What Impact Will the Results of the FTY-720 FREEDOMS Clinical Trial Have on Neurologists’ Perceptions of Emerging Oral Agents in Multiple Sclerosis?
SEPTEMBER 11, 2009
Eli Lilly Pulls the Plug on Arzoxifene – How Will its Termination Impact the Osteoporosis and Osteopenia Markets?
AUGUST 13, 2009
Dirucotide’s Demise Changes the Forecast for Multiple Sclerosis – Who Will Get the Projected $890 Million?
AUGUST 12, 2009
The Question is Raised: How Would the Alzheimer’s Disease Market Evolve if the Amyloid Hypothesis Were Debunked?
AUGUST 11, 2009
Will GlaxoSmithKline/Shionogi’s Novel HIV Agent be a Formidable Competitor to Other Integrase Inhibitors?
JULY 8, 2009
Pfizer’s Oral Jak-3 Inhibitor: A Formidable Competitor to Humira and Enbrel or Just Buzz?
JUNE 30, 2009
The Good, The Bad and The Efficacy – No Higher Than Expected Risk for Acute Pancreatitis; Elevated Risk for Bone Fractures; and Dapagliflozin’s Novel Mechanism of Action
MAY 27, 2009
The Impact of Cimzia’s Launch on the U.S. Rheumatoid Arthritis Drug Market: Stealing Market Share from Other TNF-alpha Inhibitors?
